HilleVax (HLVX) Stock Forecast, Price Target & Predictions
HLVX Stock Forecast
HilleVax stock forecast is as follows: an average price target of $32.00 (represents a 1584.21% upside from HLVX’s last price of $1.90) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
HLVX Price Target
The average price target for HilleVax (HLVX) is $32.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $34.00 to $30.00. This represents a potential 1584.21% upside from HLVX's last price of $1.90.
HLVX Analyst Ratings
According to 3 Wall Street analysts, HilleVax's rating consensus is 'Hold'. The analyst rating breakdown for HLVX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
HilleVax Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 21, 2024 | Stephen Willey | Stifel Nicolaus | $34.00 | $15.87 | 114.24% | 1689.47% |
| May 25, 2022 | David Risinger | Leerink Partners | $30.00 | $10.11 | 196.74% | 1478.95% |
The latest HilleVax stock forecast, released on Mar 21, 2024 by Stephen Willey from Stifel Nicolaus, set a price target of $34.00, which represents a 114.24% increase from the stock price at the time of the forecast ($15.87), and a 1689.47% increase from HLVX last price ($1.90).
HilleVax Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $34.00 |
| Last Closing Price | $1.90 | $1.90 | $1.90 |
| Upside/Downside | -100.00% | -100.00% | 1689.47% |
In the current month, the average price target of HilleVax stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to HilleVax's last price of $1.90. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 09, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
| Jul 08, 2024 | Guggenheim | Buy | Neutral | Downgrade |
| May 25, 2022 | SVB Leerink | - | Outperform | Initialise |
| May 24, 2022 | Guggenheim | - | Buy | Initialise |
HilleVax's last stock rating was published by H.C. Wainwright on Jul 09, 2024. The company Downgrade its HLVX rating from "null" to "Neutral".
HilleVax Financial Forecast
HilleVax Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | - |
| Surprise % | - | - | - |
HilleVax's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. HLVX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
HilleVax EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict HLVX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than HilleVax's previous annual EBITDA (undefined) of $NaN.
HilleVax Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| Net Income | - | - | - |
| Avg Forecast | $-15.06M | $-20.51M | $-38.43M |
| High Forecast | $-15.06M | $-16.60M | $-38.43M |
| Low Forecast | $-15.06M | $-25.88M | $-38.43M |
| Surprise % | - | - | - |
HilleVax's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HLVX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
HilleVax SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
HilleVax's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to HLVX last annual SG&A of $NaN (undefined).
HilleVax EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EPS | - | - | - |
| Avg Forecast | $-0.31 | $-0.42 | $-0.78 |
| High Forecast | $-0.31 | $-0.34 | $-0.78 |
| Low Forecast | $-0.31 | $-0.53 | $-0.78 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, HilleVax's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HLVX previous annual EPS of $NaN (undefined).
HilleVax Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HLVX | HilleVax | $1.90 | $32.00 | 1584.21% | Hold |
| IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
| PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
| STTK | Shattuck Labs | $1.16 | $12.00 | 934.48% | Hold |
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| PEPG | PepGen | $6.79 | $29.50 | 334.46% | Buy |
| OPT | Opthea | $4.21 | $14.00 | 232.54% | Buy |
| STRO | Sutro Biopharma | $3.69 | $11.14 | 201.90% | Buy |
| VIGL | Vigil Neuroscience | $3.87 | $11.00 | 184.24% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| PHVS | Pharvaris | $23.93 | $39.67 | 65.78% | Buy |
| CNTA | Centessa Pharmaceuticals | $15.89 | $21.67 | 36.38% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| TRDA | Entrada Therapeutics | $17.77 | $18.00 | 1.29% | Buy |
HLVX Forecast FAQ
Is HilleVax a good buy?
No, according to 3 Wall Street analysts, HilleVax (HLVX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of HLVX's total ratings.
What is HLVX's price target?
HilleVax (HLVX) average price target is $32 with a range of $30 to $34, implying a 1584.21% from its last price of $1.9. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will HilleVax stock go up soon?
According to Wall Street analysts' prediction for HLVX stock, the company can go up by 1584.21% (from the last price of $1.9 to the average price target of $32), up by 1689.47% based on the highest stock price target, and up by 1478.95% based on the lowest stock price target.
Can HilleVax stock reach $3?
HLVX's average twelve months analyst stock price target of $32 supports the claim that HilleVax can reach $3 in the near future.
What are HilleVax's analysts' financial forecasts?
HLVX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-73.988M (high $-70.083M, low $-79.359M), average SG&A $0 (high $0, low $0), and average EPS is $-1.504 (high $-1.425, low $-1.614).